Selecting the right sites is one of the most critical and challenging steps in clinical trials. Yet, many sponsor organizations still rely on outdated processes, siloed data, and manual workflows that slow everything down and increase risk.
In this shortcast, Pramod Sachdeva, Founder and Managing Director of Princeton Blue, explores how process automation is helping pharmaceutical and biotech companies rethink study and site feasibility.
Rather than building new systems from scratch, Pramod explains how modern automation platforms can connect existing systems, unify fragmented data, and provide a clearer view of site performance and patient populations, all while maintaining compliance.
You’ll hear why:
- Traditional feasibility approaches create blind spots just when speed and accuracy matter most
- Unified data views are changing how feasibility teams, sponsors, and CROs make decisions
- Process automation opens the door to faster, smarter site selection
With over two decades of experience helping global life sciences organizations embrace automation, Pramod brings a practical perspective on how to tackle one of clinical operations’ most pressing challenges.
This 2-minute listen offers a fresh take on feasibility – one that could help you accelerate decisions, strengthen collaboration, and set your trials up for success.
Don’t miss this quick but insightful conversation on the future of site selection in clinical trials.
